Navigation Links
Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
Date:11/24/2009

Laser-type device to be coupled with Stem Cell Therapy.

San Diego, CA (PRWEB) November 24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market.

“Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest’s planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company’s Stem Cell / Photoceutical therapy.” said David Koos, Chairman and CEO of Entest. “Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraÒ technology for treating ischemic stroke patients (currently in Phase III clinical trials).”

Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD.

Ernest’s goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/Entest_Biomedical/laser_device_COPD/prweb3253704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
2. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
3. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
4. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
5. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
6. Biomedical Research Centre searches for immunological biomarkers
7. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
8. Sponsor-A-Scientist: New Option to Fund Biomedical Research
9. Biomedical Research Centre developing enhanced cells as therapies
10. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
11. New test for safer biomedical research results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller Agency, a ... in the greater Birmingham area, is joining the Chris Hammond Youth Foundation in ... the region. , The Chris Hammond Youth Foundation maintains athletic facilities in rural ...
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced ... odor-control solution for colleges and universities at the APPA 2017 Annual Conference ... cannabis and tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
(Date:7/21/2017)... ... 2017 , ... The Margarian Law Firm has filed a class action ... for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ... alleges Canada Dry Ginger Ale claims on its bottle that it is made from ...
(Date:7/21/2017)... ... 21, 2017 , ... The Visiting Nurse Association of ... R. Bard Foundation, Inc. to support the music therapy program offered at ... the nonprofit home care agency. Using evidence-based methods, professionally trained and certified music ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
(Date:7/11/2017)... 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing a ... who suffer from painful intercourse and other painful pelvic pain conditions such ... to menopause. ... LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a void ...
Breaking Medicine Technology: